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1. Introduction
  One of the major limitations in the currently available 
treatment modalities for cancer is their side effects[1]. Hence 
alternate treatment for cancer is being tested. Plant derived 
natural products such as flavonoids, terpenes, alkaloids and 
so on have received considerable attention in recent years 
due to their diverse pharmacological properties including 
cytotoxic and cancer chemopreventive properties[2-3]. 
Information on the ethnopharmacologic use of plants has 
given important lead in the cancer drug development. One 
of the best approaches in search for anticancer agents from 
plant resources is the selection of plant based on ethno 
medical leads and testing the selected plant’s efficacy and 
safety in light of modern science. 
  Calotropis gigantea L. (C. gigantea), locally known as 
Boro Akanda belongs to the Asclepiadaceae family and it 
grows in tropical region and most abundant in Bangladesh, 
India, Burma, Pakistan and in the sub Himalayan tract[4]. 
Traditionally extracts and preparations from roots and 
leaves of C. gigantea are used against abdominal tumours, 
boils, syphilis, tuberculous, leprosy, skin diseases, piles, 
wounds, rheumatism and insect-bites. Root bark of this 
plant is used in dysentery and as a purgative, alterative, 
diaphoretic and emetic[5]. Antipyretic, analgesic, 
anticonvulsant, anxiolytic, sedative, hepatoprotective, 
wound healing, antidiabetic, larvicidal, anti-inflammatory 
and anti-diarrhoeal activities of C. gigantea have been 
scientifically proven[6-14]. Several phytochemicals 
have been isolated from C. gigantea and they include 
cytotoxic cardenolides[15-17], antifeedant nonprotein amino 
acid[18], naphthalene and terpene derivatives[19], flavonol 
glycosides[20], pregnanes[21-23], ursane-type triterpenoids[5] 
and steroids[24-25]. In the present communication, the 
crude methanol extract of root bark of C. gigantea and its 
petroleum ether (40-60 曟) and chloroform soluble fractions 
were evaluated for their antitumour activity against Ehrlich 
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Ascites Carcinoma (EAC) cells in mice.
2. Materials and methods
2.1. Plant material
  The root bark of C. gigantea was collected from the 
relevant area (Meherchandi) of Rajshahi University 
Campus, Rajshahi, Bangladesh in November, 2010. The 
plant was taxonomically identified by Professor A. T. M. 
Naderuzzaman, Department of Botany, Rajshahi University 
and a voucher specimen (No. 1A. Alam, Collection date 
15.08.2004) was kept in the Department of Botany, Rajshahi 
University.
2.2. Extraction 
  The pulverized plant material (1.0 kg) was extracted with 
methanol (2.0 L) at room temperature for two weeks. The 
methanol extract was concentrated and yielded 38.6 g of a 
crude extract (ME). The crude extract (25.0 g) was suspended 
in H2O and partitioned with petroleum ether (40-60 曟
) and chloroform successively to yield 13.8 g and 10.5 g 
petroleum ether (PEF) and chloroform (CF) soluble fractions, 
respectively[26].
2.3. Animals
  Male Swiss albino mice (25-30 g) were procured from the 
Animal Research Branch of the International Centre for 
Diarrhoeal Diseases and Research, Bangladesh (ICDDR,B). 
They were used throughout the study and housed in iron 
cages in a controlled environment (temperature 25依2 曟 and 
12h dark/light cycle) with standard laboratory diet and water 
ad libitum. Experiments were carried out in accordance 
with the Ethical Committee Guidelines laid down by the 
local committee regarding the care and use of animals for 
experimental procedures.
2.4. Tumour cells 
  EAC cells were obtained by the courtesy of Indian Institute 
for Chemical Biology (IICB), Kolkata, India and were 
maintained by weekly intraperitoneal (i.p.) inoculation of 105 
cells/mouse in the laboratory.
2.5. Acute toxicity studies
  An acute toxicity study relating to the determination of LD50 
was performed in mice by the method of Lorke[27]. For each 
sample, this method was carried out in twenty animals, four 
per treatment group and widely different dose ranges of 100, 
200, 400, 800 and 1 600 mg/kg body weight. Then after 24 
hrs,
the mortality number caused by each test sample was 
observed from which the median lethal dose (LD50) of ME, 
PEF and CF was determined.
2.6. Cell growth inhibition
  In vivo tumour cell growth inhibition was carried out by the 
method as described by Senthilkumar et al[28]. 2伊105 EAC 
cells were inoculated into 8 groups of mice (6 in each) on 
day 0. The groups and the design of the experiment were as 
follows:
  Group 1: EAC + 2% Dimethylsulfoxide (DMSO)
  Group 2: EAC + ME (10 mg/kg b.wt; i.p.)
  Group 3: EAC + ME (20 mg/kg b.wt; i.p.)
  Group 4: EAC + PEF (40 mg/kg b.wt; i.p.)
  Group 5: EAC + PEF (80 mg/kg b.wt; i.p.)
  Group 6: EAC + CF (20 mg/kg b.wt; i.p.)
  Group 7: EAC + CF (40 mg/kg b.wt; i.p.)
  Group 8: EAC + Bleomycin (0.3 mg/kg b.wt; i.p.)
  Treatment was continued for 5 days and on day 6 after 
tumour transplantation, animals were sacrificed. Tumour 
cells were collected by repeated washing with 0.9% saline 
and viable tumour cells per mouse of the treated group were 
compared with those of control.
2.7. Studies on survival time, hematological and biochemical 
parameters
  Swiss Albino mice were divided into nine groups (n = 12). 
All the animals were injected with EAC cells (2伊105 cells/
mouse) intraperitoneally except for the normal control group. 
This was taken as day 0. Group 1 served as the normal 
control and group 2 served as the tumour control. These two 
groups received 2% DMSO. Group 3, 4, 5, 6, 7 and 8 were 
treated with methanol extract and its petroleum ether and 
chloroform soluble fractions at 10 and 20 mg/kg body weight, 
respectively. Group 9, which served as the positive control, 
was treated with bleomycin at 0.3 mg/kg body weight. All 
these treatment were given 24 h after the tumour inoculation, 
once daily for 10 days. Six mice from each group were 
sacrificed on 14th day after tumor inoculation for the study of 
hematological and biochemical parameters. Hematological 
parameters (Hemoglobin, RBC, WBC and Differential count 
of WBC) were measured from freely flowing tail vein blood 
of each mice of each group[29]. Then every mouse was 
sacrificed and blood was collected by heart puncture. The 
blood samples of each animal were allowed to clot for 45 min 
at 4 曟. Serum was separated by centrifugation at 4 000 rpm 
for 10 minutes and analyzed for serum alkaline phosphatase 
(SALP), serum glutamate pyruvate transaminase (SGPT) and 
serum glutamate oxaloacetate transaminase (SGOT) in an 
Bioanalyzer (Microlab 200) using commercial kits (Atlas 
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Medica, UK). The rest of the animal groups were kept to 
check the survival time of EAC-tumor bearing mice.
2.8. Statistical Analysis
  All values were expressed as mean 依 SEM (Standard Error 
of Mean). Statistical analysis was performed with one way 
analysis of variance (ANOVA) followed by Dunnett’s t- test 
using SPSS statistical software of 12 version. P<0.05 were 
considered to be statistically significant when compared 
with control. 
3. Results
  The LD50 value of ME, PEF and CF was evaluated in 
Swiss albino mice and found to be 259.2, 905.1 and 
482.5 mg/kg body weight, respectively. The average 
number of viable tumour cells per mouse of tumour 
control group was found to be (5.12 依 0.18) 伊 107 
cells/mL. Treatment with ME (10 and 20 mg/kg),
PEF (80 mg/kg) and CF (20 and 40 mg/kg) decreased the 
viable cells significantly (P<0.05) (Figure 1A).
  The effect of ME, PEF and CF on the survival of tumor-
bearing mice is shown in Figure 1B and 1C. The mean 
survival time (MST) for the control group was 19.8依0.47 days, 
whereas it was 26.8依2.14, 28.5依1.62 (P<0.05), 24.1依0.92, 25.1依
1.80, 26.5±1.43, 31.1依1.52 and 39.0依0.85 (P<0.05) days for the 
groups treated with ME (10 and 20 mg/kg), PEF (40 and 80 mg/kg)
and CF (20 and 40 mg/kg) and bleomycin (0.3 mg/kg) 
respectively. Among the test samples, the highest increase in 
the lifespan of tumor-bearing mice treated with CF (40 mg/kg)
was found to be 57.07% as compared to the control group 
whereas it was 96.97% for bleomycin (0.3 mg/kg). PEP did 
not show significant efficacy to increase the MST of EAC cell 
bearing mice.
  Hematological parameters of tumor-bearing mice on day 
14 showed significant changes when compared with the 
normal mice (Table 1). The total WBC count was found to 
increase with a reduction in the hemoglobin content of RBC. 
The differential count of WBC showed that the percentage 
of neutrophils increased (P<0.05) while that of lymphocytes 
decreased (P<0.05). At the same time interval, ME (10 
and 20 mg/kg) and CF (20 and 40 mg/kg) treatment could 
change these altered parameters to near normal whereas no 
significant change was found for PEF. 
  Mice of EAC control group showed significant (P<0.05) 
increase in the activities of ALP and SGOT when compared 
with the respective normal values (Table 1). Significant 
(P<0.05) depletion in the activities of ALP and SGOT was 
found by treatment with ME (at 10 and 20 mg/kg) and CF (20 
and 40 mg/kg). At 0.3 mg/kg dose, bleomycin significantly 
(P<0.05) decreases the activities of ALP and SGOT. However 
SGPT was not significantly altered by tumour growth in only 
EAC cell bearing mice but treatment of ME (at 20 mg/kg) and 
CF (at 40 mg/kg) increased SGPT (P<0.05) when compared 
with only EAC cell bearing mice.
EAC only
EAC+ME(20 mg/kg)
EAC+PEF(80 mg/kg)
EAC+CF(40 mg/kg)
EAC+ME(10 mg/kg)
EAC+PEF(40 mg/kg)
EAC+CF(20 mg/kg)
EAC+Bleomycin(0.3 mg/kg)
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Figure 1. Effect of ME, PEF and CF on EAC cell bearing mice. 
A: Viable EAC cells on day 6 after tumor cell inoculation.
B: Mean survival time
C: % Increase in life span
Data are expressed as mean 依 S.E.M (n = 6); *P<0.05: between EAC 
control and treated group.
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Table 1 
Effect of ME, PEF and CF on hematological and biochemical parameters of EAC cell bearing mice.
Parameters
Treatment (mg/kg body weight)
Normal
EAC +
Vehicle
EAC + ME
(10 mg/kg )
EAC + ME
(20 mg/kg)
EAC + PEF
(40 mg/kg)
EAC + PEF
(80 mg/kg)
EAC + CF
(20 mg/kg)
EAC + CF
(40 mg/kg)
EAC + Bleomycin 
(0.3 mg/kg)
Hgb (g/dL) 12.05 依0.34   6.61 依0.11*   8.16 依0.21t   9.78 依0.19t   6.21 依0.29  6.73 依0.16  9.51 依0.24t   10.15 依0.25t 14.37 依0.25t
RBC(伊109 cells/mL)   6.10 依0.05   2.98 依0.04*   3.76 依0.03t   4.24 依0.03t   2.97 依0.04  3.28 依0.09  4.01 依0.05t   4.56 依0.04t   4.90 依0.09t
WBC(伊106 cells/mL)   5.83 依0.53   17.5 依0.99*   12.3 依0.66t   10.2 依0.98t   17.6 依1.22  16.5 依0.61  11.3 依0.71t   8.16 依0.60t   9.37 依0.59t
Lymphocytes (%)   69.5 依0.76   35.3 依1.17*   42.2 依1.30t   46.6 依0.49t   34.2 依1.24   38.6 依1.33  45.8 依1.49t   53.1 依1.55t 68.25 依0.90t
Neutrophils (%)   26.6 依1.28   60.5 依1.33*  53.6 依1.62   49.0 依1.06t    62.5 依1.64t   55.8 依1.70  50.3 依1.40t   43.6 依1.22t 28.87 依0.93t
Monocytes (%)   2.5 依0.3   2.6 依0.33    2.7 依0.34    2.5 依0.42     2.0 依0.44     3.0 依0.36   2.5 依0.22    2.1 依0.42  2.00 依0.27
ALP (U/L) 113.1 依1.35 293.0 依1.70* 253.6 依1.38t 168.5 依1.24t 287.2 依1.66 266.6 依3.62 187.3 依1.57t 163.7 依1.25t  133.1 依0.72t
SGPT (U/L)   56.3 依0.52 51.3 依1.12  53.0 依1.85   79.1 依2.93t   51.5 依1.84   56.3 依0.70  62.4 依1.47 83.3 依1.16t    71.3 依0.36t
SGOT (U/L)   45.1 依1.10 290.3 依1.00* 205.2 依1.55t 154.3 依1.95t 287.9 依1.94 277.9 依1.58 206.1 依0.92t 184.7 依1.51t    80.0 依0.78t
Data are expressed as mean 依S.E.M. for eight animals in each group.  *P<0.05: against normal group and tP<0.05: against EAC control group.
4. Discussion
  In EAC tumor bearing mice, a regular rapid increase in 
ascitic tumor volume was observed. Ascitic fluid is the 
direct nutritional source for tumor cells and a rapid increase 
in ascitic fluid with tumor growth would be a means to 
meet the nutritional requirement of tumor cells[30-36]. In 
this investigation, treatment with ME and CF decreased the 
viable tumor cell count and increased the life span of the 
tumor bearing mice. The reliable criteria for judging the 
value of any anticancer drug are the prolonga-tion of the life 
span of animals[37]. ME and CF by decreasing the nutritional 
fluid volume and arresting the tumor growth increases the 
life span of EAC-bearing mice. Thus, ME and CF has potent 
antitumor activity against EAC bearing mice.
  Myelosupression is a frequent and major complication of 
cancer chemotherapy[38]. In this study, ME and CF treatment 
and subsequent tumor inhibition resulted in appreciable 
improvements in hemoglobin content, RBC and WBC 
counts. These observations assume great significance, 
as anemia is a common complication in cancer and the 
situation aggravates further during chemotherapy since a 
majority of antineoplastic agents exert suppressive effects 
on erythropoiesis[39] and thereby limiting the use of these 
drugs. The improvement in hematological profile of the 
tumor bearing mice following the treatment with ME and CF 
could be due to the action of the different phytoconstituents 
present in the extract and fraction.
  Numerous studies on the enzymes of carbohydrate 
metabolism in cancer showed that actively dividing 
neoplastic tissues require more energy than normal 
cells[40]. The consequent display of a high rate of glycolysis 
in malignant conditions is clinically manifested in the 
increased activity of several serum enzymes[41,42]. In our 
study, fourteen (14) days of inoculation with EAC brought 
the significant elevation in the levels of SGOT and SALP. 
Treatment with ME and CF restored the elevated biochemical 
parameters more or less to normal range thereby indicating 
the protective effect on the tumour induced complications. 
However some extent of hepatotoxicity was associated 
with the treatment of ME (20 mg/kg) and CF (40 mg/kg) 
as indicated by the elevation in the levels of SGPT. Some 
phytochemicals present in ME and CF may be responsible 
for this elevation. 
  The result of the present investigation is quite encouraging 
and it explores in vivo the potent anticancer activity of ME 
and CF of root bark of C. gigantea L. probably because 
of its direct cytotoxic effect. No significant results were 
obtained for PEF. In vitro some phytochemicals with potent 
cytotoxic effect have already been reported from the 
root bark of C. gigantea[23,15]. Our preliminary thin layer 
chromatography (TLC) screening also showed that ME and 
CF contained flavonoid, glycosides, saponin, steroids and 
terpenoids type compounds. Many such type of compounds 
are known to possess potent antitumor properties[43]. Further 
investigations are in progress in the laboratory to identify 
the active principles involved in this antitumor activity and 
investigate the mechanism of inhibition.
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